clinical trial · NCT07076095
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.·phase2·not yet recruiting·n = 200
Small Cell Lung CancerIBB0979topotecan hydrochloride for injection
brief summary
This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).
started
Aug 1, 2025
primary completion
Aug 1, 2028
completion
Aug 1, 2031
last updated
Jul 21, 2025
official title
A Phase II/III Study to Compare IBB0979 in Combination With Topotecan Versus Topotecan in Subjects With Relapsed Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol